InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,459.20
(
0.23%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.52
(
0.47%
)
Bitcoin
65,136.95
(
1.78%
)
Post# of 43
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

tykundegex

Send PM Follow Ignore
Followers 40
Posts 3318
Boards Moderated 0
Alias Born 08/18/2009

tykundegex

Re: None

Wednesday, 08/17/2011 6:20:35 AM

Wednesday, August 17, 2011 6:20:35 AM

Post# of 43
New Edison report out (after CEO hire):

http://www.addexpharma.ch/fileadmin/user_upload/Financial_documents/analysts_reports/A_11.08.16_Edison_-_Addex_appoints_new_CEO.pdf

Taken from the report:

Our risk-adjusted NPV of key late-stage assets in the R&D pipeline yields a valuation of CHF212m, equivalent to CHF30/share including FY11 cash. This remains based on an assumption that dipraglurant is second to market for PD-LID; hence it would increase if this compound’s competitive position improves versus Novartis’s AFQ056.

(N.B. CHF30 on the Swiss exchange SWX:ADXN, not OTC:ADDXF)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up